BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16733676)

  • 1. Monitoring therapeutic efficacy in breast carcinomas.
    Tardivon AA; Ollivier L; El Khoury C; Thibault F
    Eur Radiol; 2006 Nov; 16(11):2549-58. PubMed ID: 16733676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
    Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of 18F-FDG gamma camera PET, mammography and ultrasonography in demonstrating primary disease in locally advanced breast cancer.
    Marshall C; Mustafa S; Wheatley DC; Eremin JE; El-Sheemy M; Jibril JA; Eremin O; Griffiths PA
    Nucl Med Commun; 2004 Jul; 25(7):721-5. PubMed ID: 15208500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
    Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
    Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.
    Choi JH; Lim HI; Lee SK; Kim WW; Kim SM; Cho E; Ko EY; Han BK; Park YH; Ahn JS; Im YH; Lee JE; Yang JH; Nam SJ
    J Surg Oncol; 2010 Oct; 102(5):392-7. PubMed ID: 19877158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to therapy in breast cancer.
    Avril N; Sassen S; Roylance R
    J Nucl Med; 2009 May; 50 Suppl 1():55S-63S. PubMed ID: 19380410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients.
    An YS; Lee DH; Yoon JK; Lee SJ; Kim TH; Kang DK; Kim KS; Jung YS; Yim H
    Nuklearmedizin; 2014; 53(3):89-94. PubMed ID: 24220324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer.
    Semiglazov V
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):21-3. PubMed ID: 26063880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging surveillance of patients with breast cancer after primary treatment: current recommendations.
    Yoon JH; Kim MJ; Kim EK; Moon HJ
    Korean J Radiol; 2015; 16(2):219-28. PubMed ID: 25741186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of Breast Cancer Screening and Diagnosis.
    Lebron-Zapata L; Jochelson MS
    PET Clin; 2018 Jul; 13(3):301-323. PubMed ID: 30100072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
    Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T
    Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid
    Goorts B; Vöö S; van Nijnatten TJA; Kooreman LFS; de Boer M; Keymeulen KBMI; Aarnoutse R; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1796-1805. PubMed ID: 28600647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.